NewsRoom Articles - BioMedWire (BMW)

TuesdayMar 31, 2026 11:15 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”). LB-100 helps in the fight against cancer in a few ways, as it makes cancer cells more sensitive to immunotherapy and chemotherapy, while also disrupting cancer’s internal repair system. The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by over 25 published preclinical and translational studies so far. LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100.…

TuesdayMar 31, 2026 10:00 am

Researchers Discover Mechanism Behind Deadly Pediatric Brain Cancer

A team of scientists from Texas Children’s Hospital, University of Pittsburgh and Baylor College of Medicine has discovered the primary driver of a deadly pediatric brain cancer, PFA (posterior fossa type A) ependymoma. They identified male sex hormones called androgens as playing a key role in promoting PFA ependymoma growth. The study, whose findings appeared in the journal Nature, shows that androgens don’t play a part in the development of any other kind of brain tumor. The team’s work shows that when the signaling of these hormones is blocked, the growth of the tumors is blocked. This discovery creates a possibility that treatments could be developed to block these hormones to…

TuesdayMar 31, 2026 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition

In the life sciences industry, a robust pipeline is widely recognized as a critical driver of value creation and sustainability. The significance of the UK designation extends beyond a single program. The UK designation builds on additional regulatory recognition for dusquetide, including orphan drug designation from the FDA for Behçet’s disease. A strong and diversified pipeline is often the foundation of long-term success in the biotechnology sector, enabling companies to sustain innovation while advancing multiple therapeutic opportunities. Soligenix (NASDAQ: SNGX) is reinforcing that foundation as its investigational therapy SGX945 receives Promising Innovative Medicine designation in the United Kingdom, a development…

TuesdayMar 31, 2026 9:00 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’

Cardiovascular disease remains the leading cause of death in the United States, representing a significant and persistent healthcare burden that the company’s solutions are designed to address. Cardio Diagnostics has developed a proprietary platform that integrates epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights from a simple blood sample. The company’s clinical tests are non-invasive, require no fasting or radiation, and are designed to detect and assess coronary heart disease, including forms that may not be identified through traditional diagnostic methods. The company has established multiple commercialization channels, including provider networks, employer partnerships, and community-based programs,…

MondayMar 30, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

Researchers are increasingly focused on combination therapies and novel mechanisms of action that can enhance tumor response to treatment. LIXTE’s LB-100 is designed to sensitize cancer cells to chemotherapy and potentially enhance immune system activity, offering a complementary approach to existing treatments. The company recently announced the expansion of its ongoing clinical trial in clear cell ovarian cancer, including an increase in patient enrollment that effectively doubles the size of the study. Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need…

FridayMar 27, 2026 10:00 am

Major Discovery Could Reshape Cancer Immunotherapy

Researchers seeking new ways of fighting cancer using immunotherapy have discovered a “hidden brake” that had previously been unknown to scientists. This brake exists on immune cells and scales back their ability to combat cancer, and it acts without any influence from tumor cells. This molecule, dubbed SLAMF6, occurs naturally on fighter immune cells called T-cells. It is an inbuilt weakness on those cells and it shuts off T-cells’ capacity to kill tumor cells. In preclinical trials, the researchers turned off this switch and were able to revive the immune cells’ ability to combat cancer. The study, whose findings were…

ThursdayMar 26, 2026 10:30 am

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

LIXT is developing LB-100, a first-in-class therapy designed to enhance the effectiveness of established cancer treatments while cutting down toxicity Strategic partnership with Liora Technologies integrates multimodal oncology data, enabling precision-guided patient care and streamlined clinical trials These developments position the company at the intersection of innovation and therapeutics Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side…

ThursdayMar 26, 2026 10:00 am

Hackers Linked to Iran Target Another US Health Care Institution

On Tuesday this week, researchers revealed that a group of hackers linked to the Iranian government had targeted another United States medical institution toward the end of February prior to the onset of the current military conflict between the U.S., Israel and Iran. This is the second such attack. This attack is noteworthy because this information comes on the heels of another attack in which Stryker, a medical device firm in America, was targeted and had its data deleted. Handala, a hacktivist group linked to Iran, claimed responsibility for this attack that resulted in about 80,000 systems being deleted. Stryker is currently restoring its systems and the attack has now been contained. It isn’t clear whether other attacks have happened…

ThursdayMar 26, 2026 9:00 am

Earth Science Tech Inc. (ETST) Builds Integrated Healthcare Platform for Scalable Growth

ETST is focused on compounding pharmacies, telemedicine, and clinical services Vertically integrated model supports recurring, patient-driven revenue The company’s strategy aligns with increased demand for personalized and digital healthcare Earth Science Tech (OTC: ETST) is consolidating on its identity as a leading healthcare holding company, implementing a strategy built on vertical integration across telemedicine, pharmaceuticals, and clinical services. The company’s transitioning from legacy operations highlights a distinct alignment with high-growth segments of the healthcare sector, particularly personalized medicine and digital care delivery (ibn.fm/9lMJg). At the nucleus of ETST’s model are its compounding pharmacy operations, which produce customized medications tailored for specific…

TuesdayMar 24, 2026 11:15 am

Heartbeam Inc. (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation

The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate AI-based ECG Algorithms The collaboration is focused on building next-generation, personalized AI-ECG algorithms for wellness and clinical applications, including assessing heart attack risk HeartBeam’s role in this evolving landscape is anchored by its HeartBeam System HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push to expand its role in next-generation cardiac monitoring. The announcement highlights HeartBeam’s growing focus on artificial intelligence (“AI”)-enabled analysis and reinforces the relevance of its technology…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

Researchers Discover Mechanism Behind Deadly Pediatric Brain Cancer

Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

Major Discovery Could Reshape Cancer Immunotherapy

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

Hackers Linked to Iran Target Another US Health Care Institution

Earth Science Tech Inc. (ETST) Builds Integrated Healthcare Platform for Scalable Growth

Heartbeam Inc. (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search